Format

Send to

Choose Destination
Trends Immunol. 2015 Oct;36(10):651-662. doi: 10.1016/j.it.2015.08.004.

GM-CSF in Neuroinflammation: Licensing Myeloid Cells for Tissue Damage.

Author information

1
Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
2
Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland. Electronic address: becher@immunology.uzh.ch.

Abstract

Multiple sclerosis (MS) is the prototypical inflammatory disease of the central nervous system (CNS). MS lesions harbor different immune cells, but the contribution of individual cell types to disease etiology and progression is not well understood. In experimental autoimmune encephalomyelitis (EAE), auto-reactive helper T (Th) cells instigate CNS inflammation by acting on myeloid cells via the production of granulocyte-macrophage colony-stimulating factor (GM-CSF). Recent reports have implicated myeloid cells in both the inflammatory process and as executers of tissue damage in the CNS. We review these findings here, and integrate them into a model wherein GM-CSF produced by Th cells coordinates monocyte recruitment to the CNS, and differentiation into pathogenic effectors. We discuss the implications of this model to current therapies for MS, and outline important areas of further inquiry.

KEYWORDS:

CNS; GM-CSF; MS; monocytes; neuroinflammation; tissue damage

PMID:
26431942
DOI:
10.1016/j.it.2015.08.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center